Ali Ghasemzadeh, MD, PhD (@aghasemzadeh1) 's Twitter Profile
Ali Ghasemzadeh, MD, PhD

@aghasemzadeh1

Urology PGY-5 @wiscurology | @hopkinsmedicine MSTP alum | interested in GU oncology, T cell biology, and antibodies.

ID: 947877681827328000

calendar_today01-01-2018 17:10:24

56 Tweet

298 Followers

328 Following

Cancer Immunology Research (@cir_aacr) 's Twitter Profile Photo

Register for the AACR Virtual Journal Club, May 14 at 2 pm ET! Charles Drake Herbert Irving Comprehensive Cancer Center discusses his paper, "Longitudinal Immune Profiling During Cancer Immunoediting." bit.ly/3tlOwIO

Register for the <a href="/AACR/">AACR</a> Virtual Journal Club, May 14 at 2 pm ET! Charles Drake  
<a href="/columbiacancer/">Herbert Irving Comprehensive Cancer Center</a> discusses his paper, "Longitudinal Immune Profiling During Cancer Immunoediting." bit.ly/3tlOwIO
Casey Ager (@caseyager) 's Twitter Profile Photo

Couldn’t be prouder to have worked with the Drake and Califano teams at Herbert Irving Comprehensive Cancer Center on this project, now out today in Cell. Special shout-out to first authors Aleks,Niv Chowdhury, and Scott Haake, MD, PhD for their hard work! authors.elsevier.com/c/1d5-5L7PXe~U…

Delgoffe Lab (@delgoffelab) 's Twitter Profile Photo

How does one define exhaustion? As many have shown with ATACseq (E. John Wherry, Nick Haining, etc.), exhausted T cells are a lineage: posessing a relatively fixed chromatin landscape with unique accessible regions that define them the way Th1 vs Th2 are defined.

NatureRevClinOncol (@natrevclinoncol) 's Twitter Profile Photo

In pts with ccRCC, high AXL expression levels in tumour cells is associated high PD-L1 expression, especially in VHL mutated cells, and with lower ORRs and a trend to shorter PFS following second-line anti-PD-1 treatment: clincancerres.aacrjournals.org/content/early/… #kcsm #ImmunoOnc

Alexis Combes (@alexis_combes) 's Twitter Profile Photo

Online today Cell. By identifying and classifying recurrent immune features, we discovered 12 unique dominant tumor Archetypes that span cancer types. This immune-based classification provides a framework toward understanding tumor immunity to guide immunotherapies 1/n.

Online today <a href="/CellCellPress/">Cell</a>. By identifying and classifying recurrent immune features, we discovered 12 unique dominant tumor Archetypes that span cancer types. This immune-based classification provides a framework toward understanding tumor immunity to guide immunotherapies 1/n.
Bishai Lab (@bishailab) 's Twitter Profile Photo

A new candidate vaccine against NMIBC in a multi institutional study in close collaboration with Trinity J. Bivalacqua Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against… disq.us/t/457gd6d

Cancer Cell (@cancer_cell) 's Twitter Profile Photo

Online Now: Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulators dlvr.it/SnDDKT

Roger Li (@urogerlimd) 's Twitter Profile Photo

Results from our Ph2 study using Durva in BCG Unresponsive CIS is online Clinical Cancer Research 👉2/17 CR at 6mo 👉1/17 Gr 3 hepatotoxicity 👉1/17 PD-L1 high pre-treatment doi.org/10.1158/1078-0… #JingsongZhang Wade J Sexton Philippe spiess @sgilbert1973 Julio Pow-Sang #JRCG Moffitt Urologic Oncology Fellowship

Results from our Ph2 study using Durva in BCG Unresponsive CIS is online <a href="/CCR_AACR/">Clinical Cancer Research</a> 
👉2/17 CR at 6mo
👉1/17 Gr 3 hepatotoxicity
👉1/17 PD-L1 high pre-treatment
doi.org/10.1158/1078-0…
#JingsongZhang <a href="/WadeJSexton9/">Wade J Sexton</a> <a href="/SpiessPhilippe/">Philippe spiess</a> @sgilbert1973 <a href="/JulioPowSangMD/">Julio Pow-Sang</a> #JRCG <a href="/MoffittGUOnc/">Moffitt Urologic Oncology Fellowship</a>
Kaechlab (Sue Kaech) (@tcellogic) 's Twitter Profile Photo

Fascinating discovery by @Annaglobig! Exhausted CD8 T cells talk to sympathetic nerves in tissues & tumors. Tex cells express ADRB1 and localize near sympathetic nerves, listening to stress hormone noradrenaline. This promotes their dysfunction. nature.com/articles/s4158…

NEJM (@nejm) 's Twitter Profile Photo

Platinum-based chemotherapy is the standard of care for previously untreated unresectable or metastatic urothelial carcinoma, w/ cisplatin-based chemotherapy preferred for eligible pts. Full CheckMate 901 trial Research Summary by Michiel van der Heijden et al.: nej.md/3FmKbO6

Tom Powles (@tompowles1) 's Twitter Profile Photo

Enfortumab + Pembro outperforms platinum chemotherapy in advanced UC with a doubling of PFS and a halving of the risk of death @nejm. G3/4 AEs of 56% for EVP vs 70% for chemo & CR=29%. Editorial by @gniegisch ‘EVP is the new standard against which future trials must be compared’

Enfortumab + Pembro outperforms platinum chemotherapy in advanced UC with a doubling of PFS and a halving of the risk of death @nejm.  G3/4 AEs of 56% for EVP vs 70% for chemo &amp; CR=29%. Editorial by @gniegisch ‘EVP is the new standard against which future trials must be compared’
Daniel Shapiro (@d_shapiro1) 's Twitter Profile Photo

Great job to our UW Urologic Oncology UW Urology students, residents, and fellow presenting their research at Wisconsin urological society meeting. No one moderates better than #MikeRisk

Great job to our <a href="/WiscUroOnc/">UW Urologic Oncology</a> <a href="/wiscurology/">UW Urology</a> students, residents, and fellow presenting their research at Wisconsin urological society meeting. No one moderates better than #MikeRisk
Tom Powles (@tompowles1) 's Twitter Profile Photo

NIAGARA’s surgical safety results #EAU25 with Jim Catto. Results show the addition of duvalumab to neoadjuvant platinum chemotherapy did not increase surgical complications or cystectomy rates.

NIAGARA’s surgical safety results #EAU25 with Jim Catto. Results show the addition of duvalumab to neoadjuvant platinum chemotherapy did not increase surgical complications or cystectomy rates.
The Nobel Prize (@nobelprize) 's Twitter Profile Photo

BREAKING NEWS The 2025 #NobelPrize in Physiology or Medicine has been awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi “for their discoveries concerning peripheral immune tolerance.”

BREAKING NEWS
The 2025 #NobelPrize in Physiology or Medicine has been awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi “for their discoveries concerning peripheral immune tolerance.”